转移性透明细胞肾细胞癌的管理:ASCO指南
ASCO专家小组通过系统文献综述,为转移性透明细胞肾细胞癌(ccRCC)的管理提供推荐。推荐涵盖诊断时组织活检及标志物检测、IMDC风险分层指导治疗、减瘤性肾切除术的选择、主动监测的适用条件、一线系统治疗(ICI联合VEGFR TKI或双药方案)、后线治疗及骨/脑转移和肉瘤样特征的处理,并鼓励临床试验参与。
要点
- 转移性ccRCC诊断应基于原发灶或转移灶组织活检并纳入标志物/染色支持诊断。
- 应采用IMDC风险标准指导治疗决策。
- favorable风险需系统治疗者可予ICI联合VEGFR TKI;中/低风险者应给予双药方案。
核心结论
- ASCO专家小组针对转移性ccRCC的管理提供了基于系统文献综述的推荐,涵盖诊断、风险分层、减瘤性肾切除术、主动监测、一线及后线系统治疗和特殊部位转移处理。
- 推荐鼓励转移性ccRCC患者参与临床试验。
研究设计与样本
- ASCO专家小组 conducted 系统文献综述以获取指导治疗推荐的证据。
- 专家小组考虑了以英文发表的同行评议报告。
主要发现
- 专家小组基于同行评议报告形成推荐,涉及诊断活检、IMDC风险标准、减瘤性肾切除术、主动监测、一线系统治疗、后线治疗及骨/脑转移和肉瘤样特征的处理。
关键数值与推荐
- 转移性ccRCC的诊断应使用原发肿瘤或转移部位的组织活检,并纳入标志物和/或染色以支持诊断。
- 应使用国际转移性RCC数据库联盟(IMDC)风险标准指导治疗。
- 对选择性的肾脏原位且 favorable 或 intermediate 风险患者,可提供减瘤性肾切除术。
- 对已行肾切除术者,若无症状且疾病负荷低,可提供初始主动监测。
- favorable 风险且需系统治疗者可提供ICI联合VEGFR TKI; intermediate 或 poor 风险者应提供双药方案(未在ICI与ICI联合VEGFR TKI之间提供推荐)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC). METHODS: An Expert Panel conducted a systematic literature review to obtain evidence to guide treatment recommendations. RESULTS: The panel considered peer-reviewed reports published in English. RECOMMENDATIONS: The diagnosis of metastatic ccRCC should be made using tissue biopsy of the primary tumor or a metastatic site with the inclusion of markers and/or stains to support the diagnosis. The International Metastatic RCC Database Consortium risk criteria should be used to inform treatment. Cytoreductive nephrectomy may be offered to select patients with kidney-in-place and favorable- or intermediate-risk disease. For those who have already had a nephrectomy, an initial period of active surveillance may be offered if they are asymptomatic with a low burden of disease. Patients with favorable-risk disease who need systemic therapy may be offered an immune checkpoint inhibitor (ICI) in combination with a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI); patients with intermediate or poor risk should be offered a doublet regimen (no recommendation was provided between ICIs or an ICI in combination with a VEGFR TKI). For select patients, monotherapy with either an ICI or a VEGFR TKI may be offered on the basis of comorbidities. Interleukin-2 remains an option, although selection criteria could not be identified. Recommendations are also provided for second- and subsequent-line therapy as well as the treatment of bone metastases, brain metastases, or the presence of sarcomatoid features. Participation in clinical trials is highly encouraged for patients with metastatic ccRCC.Additional information is available at www.asco.org/genitourinary-cancer-guidelines.
引用
- Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. J Clin Oncol. 2022. PMID: 35728020. doi:10.1200/JCO.22.00868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。